Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure Builds For Revamped Acetaminophen Warnings In Rx Dispensing Materials

This article was originally published in The Pink Sheet Daily

Executive Summary

A white paper by the National Council for Prescription Drug Programs calls on industry to harmonize Rx labeling with existing labeling for OTC medicines.

You may also be interested in...



Gilenya Off And Running, But Keeping Pace Long-Range Is Key

Novartis AG's Gilenya (fingolimod) – the first oral treatment for multiple sclerosis – is off to a modestly strong start. The drug’s sales performance since its U.S. launch in October has been respectable, if not remarkable, driven by both market expansion and patient switches.

Gilenya Off And Running, But Keeping Pace Long-Range Is Key

Novartis AG's Gilenya (fingolimod) – the first oral treatment for multiple sclerosis – is off to a modestly strong start. The drug’s sales performance since its U.S. launch in October has been respectable, if not remarkable, driven by both market expansion and patient switches.

One Acetaminophen Headache Remains Untreated: Acronyms On Pharmacy Containers

FDA hopes to curtail acetaminophen overdosing by requiring manufacturers to restrict the amount of the drug in combination Rx products. But another potential cause of overdosing remains intact: the use of acronyms on pharmacy labels.

Topics

UsernamePublicRestriction

Register

PS072735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel